Inpharmatica and Celera Genomics to jointly develop new version of Biopendium™, drug target discovery platform
London, UK and Rockville, MD, US - November 06, 2001
Inpharmatica Ltd, a leading informatics-driven drug discovery company and Celera Genomics (NYSE: CRA), an Applera Corporation business, today announced that they have entered into a joint program to develop and commercialise a new version of Inpharmatica’s Biopendium™ target and drug discovery platform. The two companies intend to combine their expertise in genomics discovery and identification of protein function to produce one of the world’s leading target discovery resources.
The new product, to be called Celera Edition Biopendium™, is expected to apply Inpharmatica’s proprietary protein structure/function prediction technology to Celera’s proprietary mammalian sequences and other public domain sequences to create a unique resource of integrated sequence, structural and functional information. Inpharmatica and Celera believe that this will result in the most comprehensive genome-wide assignment of protein function currently available, thereby reducing one of the major bottlenecks in genomics based discovery.
The Celera Edition Biopendium is expected to seamlessly link to the Celera Discovery System™ to provide a comprehensive sequence and target discovery platform that enables scientists to rapidly access novel structure-based functional annotation coupled with the comprehensive and expert-curated collection of protein sequences derived from Celera’s human and mouse genomes.
This new version of the Biopendium will be jointly developed, and co–marketed by both businesses. The product is expected to be launched in early 2002 and marketed to the pharmaceutical and life science community to better enable their target discovery and prioritization programs.
As part of the agreement, Celera will subscribe to Inpharmatica’s Biopendium database, and Inpharmatica will subscribe to the Celera Discovery System. Celera and Inpharmatica will each deploy the Celera Edition Biopendium™ for use in their respective internal discovery programs.
Jason Mollé, general manager for Celera’s online business, commenting on the agreement said, “This is the first structural bioinformatics product to incorporate Celera’s protein sequences and will, we believe, greatly enhance the drug discovery efforts of our shared customers. Our scientific quality and advanced technologies makes this a natural partnership.”
Commenting on this agreement, Malcolm Weir, CEO of Inpharmatica said, “The combination of Inpharmatica’s expertise in structural bioinformatics and Celera’s comprehensive data content should provide users with one of the most complete structure-based annotations of the human genome, making it an unrivalled target discovery system. We are delighted that Celera has chosen Inpharmatica as its partner in the application of structural bioinformatics to the proteome – wide elucidation of biochemical function.”
Inpharmatica is a leading informatics-driven drug discovery company. It applies information from its two platform technologies, which look at the relationships between the structure and function of proteins, to the discovery of novel drugs. Founded in 1998, Inpharmatica is based on research from Professor Janet Thornton's group at University College London. The Company utilises large-scale computing facilities, as well as proprietary informatics technologies, to identify drug targets and subsequently the drug compounds themselves which are most likely to be successful as therapeutics.
These two integrated platform technologies, developed by Inpharmatica, assess the suitability of proteins as drug targets. They do this by predicting the function of the protein and evaluating its druggability, i.e. whether a drug molecule can be discovered for this target.
Armed with knowledge of a protein’s function and inherent druggability, the Company is then well placed to develop novel drug molecules against that. Inpharmatica will advance the target into drug discovery in-house and with partners.Business Model:
About Applera Corporation and Celera Genomics
Applera Corporation comprises two operating groups. The Celera Genomics Group, headquartered in Rockville, MD, is engaged principally in integrating advanced technologies to create therapeutic discovery and development capabilities for internal use and for its customers and collaborators. Celera’s businesses are its online information business and its therapeutics discovery business. The online information business is a leading provider of information based on the human genome and other biological and medical information. Through the therapeutic discovery business, Celera intends to leverage its genomic and proteomic capabilities to identify drug targets and diagnostic marker candidates, and to discover novel therapeutic candidates. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2001. Celera Diagnostics has been established as a joint venture between Applied Biosystems and Celera Genomics. This new venture is focused on discovery, development and commercialization of novel diagnostic tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800.762.6923. Information about Celera is available on the World Wide Web at www.celera.com.
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as “believe,” “expect,” “anticipate,” “should,” “planned,” “estimated,” and “potential,” among others. These forward-looking statements are based on Applera Corporation’s current expectations. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of Celera Genomics’ businesses include but are not limited to (1) dependence on the continued assembly and annotation of the human and other genomes; (2) unproven use of genomics information to develop or commercialize products; (3) intense competition in the industry in which Celera Genomics operates; (4) dependence on computer hardware, software, and Internet applications; (5) potential adverse effect on Celera Genomics’ intellectual property protection and the value of its products and services due to public disclosure of genomics sequence data; (6) potential for government regulation of Celera Genomic’s or its customers’ products and services; (7) the actual timing of commercial launch of new products; and (8) other factors that might be described from time to time in Applera Corporation’s filings with the Securities and Exchange Commission.
Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.